Payment overview · 2025
General Payments
$1,071.80
58 reported records · 21 companies
Healthcare provider profile · identity verified
Mark A Simaga, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HOBART, IN · NPI 1598818270
Verified facts
What the public records show
CMS Open Payments records show Mark A Simaga, MD received $1,071.80 in general payments during 2025 across 58 reported records.
Novartis Pharmaceuticals Corporation accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa, Gamunex-C, Nurtec Odt, Qulipta, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Qulipta by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fycompa by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gamunex-C by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $255.53 | 23.8% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.19 | 17.3% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $126.21 | 11.8% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $103.66 | 9.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.25 | 5.1% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $42.53 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.31 | 3.0% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $30.37 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.84 | 2.3% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$23.20 | 2.2% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $22.63 | 2.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $22.39 | 2.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.69 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.94 | 1.7% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.90 | 1.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.03 | 1.6% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $15.28 | 1.4% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $15.26 | 1.4% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $14.99 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.73 | 1.4% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $13.87 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,071.80 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $255.53 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $154.17 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.74 | 7 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $126.21 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $103.66 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.25 | 3 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 61 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 276 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 243 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 57 |
| Levetiracetam | Levetiracetam | 164 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 162 | 34 |
| Donepezil Hcl | Donepezil Hcl | 161 | 44 |
| Clonazepam | Clonazepam | 151 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 140 | 43 |
| Pregabalin | Pregabalin | 121 | 28 |
| Alprazolam | Alprazolam | 117 | 26 |
| Lacosamide | Lacosamide | 109 | 19 |
| Memantine Hcl | Memantine Hcl | 102 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 21 |
| Aptiom | Eslicarbazepine Acetate | 81 | suppressed |
| Primidone | Primidone | 75 | 17 |
| Topiramate | Topiramate | 72 | 19 |
| Diazepam | Diazepam | 71 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 69 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 65 | 13 |
| Lorazepam | Lorazepam | 64 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 61 | 13 |
| Memantine Hcl Er | Memantine Hcl | 60 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | 11 |
| Sertraline Hcl | Sertraline Hcl | 55 | 13 |
| Tramadol Hcl | Tramadol Hcl | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Rivastigmine | Rivastigmine | 49 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 47 | 12 |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | 12 |
| Baclofen | Baclofen | 40 | 11 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Qulipta | Atogepant | 40 | suppressed |
| Fentanyl | Fentanyl | 39 | suppressed |
| Briviact | Brivaracetam | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Topiramate Er | Topiramate | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Fycompa | Perampanel | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Xcopri | Cenobamate | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,071.80 · 58 records | Novartis Pharmaceuticals Corporation | ACTHAR, AMYVID, AUSTEDO XR, Bafiertam, DAYBUE, ELIQUIS, FYCOMPA, Gamunex-C, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Motpoly XR, NURTEC ODT, Ocrevus Zunovo, QULIPTA, REXULTI, Tascenso ODT, UBRELVY, VYVGART, WAINUA, XCOPRI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error